ArticleBiomedicines2025

Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma.

Alexander S Himstead et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.